You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Combinations of Immunotherapy and Radiation in Cancer Therapy
|
|---|---|
| Published in |
Frontiers in oncology, November 2014
|
| DOI | 10.3389/fonc.2014.00325 |
| Pubmed ID | |
| Authors |
Ralph E. Vatner, Benjamin T. Cooper, Claire Vanpouille-Box, Sandra Demaria, Silvia C. Formenti |
| Abstract |
The immune system has the ability to recognize and specifically reject tumors, and tumors only become clinically apparent once they have evaded immune destruction by creating an immunosuppressive tumor microenvironment. Radiotherapy (RT) can cause immunogenic tumor cell death resulting in cross-priming of tumor-specific T-cells, acting as an in situ tumor vaccine; however, RT alone rarely induces effective anti-tumor immunity resulting in systemic tumor rejection. Immunotherapy can complement RT to help overcome tumor-induced immune suppression, as demonstrated in pre-clinical tumor models. Here, we provide the rationale for combinations of different immunotherapies and RT, and review the pre-clinical and emerging clinical evidence for these combinations in the treatment of cancer. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 17% |
| United States | 2 | 11% |
| Germany | 1 | 6% |
| Switzerland | 1 | 6% |
| Unknown | 11 | 61% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 83% |
| Scientists | 3 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 199 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 1% |
| Portugal | 1 | <1% |
| Switzerland | 1 | <1% |
| India | 1 | <1% |
| Canada | 1 | <1% |
| Japan | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 191 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 39 | 20% |
| Researcher | 33 | 17% |
| Student > Master | 27 | 14% |
| Student > Doctoral Student | 18 | 9% |
| Student > Bachelor | 16 | 8% |
| Other | 39 | 20% |
| Unknown | 27 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 61 | 31% |
| Agricultural and Biological Sciences | 35 | 18% |
| Biochemistry, Genetics and Molecular Biology | 18 | 9% |
| Immunology and Microbiology | 15 | 8% |
| Physics and Astronomy | 10 | 5% |
| Other | 17 | 9% |
| Unknown | 43 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2024.
All research outputs
#1,853,765
of 25,508,813 outputs
Outputs from Frontiers in oncology
#379
of 22,613 outputs
Outputs of similar age
#24,588
of 370,059 outputs
Outputs of similar age from Frontiers in oncology
#2
of 98 outputs
Altmetric has tracked 25,508,813 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,613 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 370,059 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.